1.Teriparatide therapy without surgical treatment for medication-related osteonecrosis of the jaw: a report of two cases
Gyeong-Yun KIM ; Woo-Seok KANG ; Hyo-Joon KIM ; Seong-Yong MOON ; Ji-Su OH
Oral Biology Research 2024;48(3):94-99
Medication-related osteonecrosis of the jaw (MRONJ) is a severe complication associated with antiresorptive or anticancer agents.Surgical intervention is generally recommended for advanced stages, but some patients may be ineligible for surgery due to systemic conditions or anatomical limitations. We present two patients who had been treated for osteoporosis with bisphosphonates and were diagnosed with stage 2 MRONJ. Their chief complaints included refractory pain, purulent discharge, and exposed bone following tooth extraction. Despite conservative treatment, the MRONJ worsened, prompting the initiation of teriparatide therapy. After teriparatide administration, the patients experienced symptom improvement, spontaneous sequestrum removal, and significant bone regeneration of vertical osteolysis. Teriparatide, a bone anabolic agent, is typically recommended as adjuvant therapy alongside surgical treatment for MRONJ. This case report illustrates the effectiveness of teriparatide monotherapy in the absence of surgical intervention, particularly for patients who cannot discontinue antiresorptive agents due to low bone mineral density.
2.Type 2 Innate Lymphoid Cells and Skin Fibrosis in a Murine Model of Atopic Dermatitis-Like Skin Inflammation
Jisun YOON ; Jiho LEE ; Arum PARK ; Jin YOON ; Jeong Ryun KIM ; Gyeong Joon MOON ; Jinho YU
Journal of Korean Medical Science 2024;39(30):e221-
Background:
Atopic dermatitis (AD) is a chronic relapsing inflammatory skin disease.Although murine studies have demonstrated that type 2 innate lymphoid cells (ILCs) mediate type 2 skin inflammation, their role in skin fibrosis in AD remains unclear. This study investigated whether type 2 ILCs are involved in skin fibrosis using an AD-like murine model.
Methods:
C57BL/6 mice were treated epicutaneously with Aspergillus fumigatus (Af) for 5 consecutive days per week for 5 weeks to induce skin fibrosis. Mature lymphocyte deficient Rag1−/− mice were also used to investigate the role of type 2 ILCs in skin fibrosis.
Results:
The clinical score and transepidermal water loss (TEWL) were significantly higher in the AD group than in the control group. The AD group also showed significantly increased epidermal and dermal thicknesses and significantly higher numbers of eosinophils, neutrophils, mast cells, and lymphocytes in the lesional skin than the control group. The lesional skin of the AD group showed increased stain of collagen and significantly higher levels of collagen than the control group (10.4 ± 2.2 µg/mg vs. 1.6 ± 0.1 µg/mg, P < 0.05). The AD group showed significantly higher populations of type 2 ILCs in the lesional skin compared to the control group (0.08 ± 0.01% vs. 0.03 ± 0.01%, P < 0.05). These findings were also similar with the AD group of Rag1−/− mice compared to their control group. Depletion of type 2 ILCs with anti-CD90.2 monoclonal antibodies significantly improved clinical symptom score, TEWL, and infiltration of inflammatory cells, and significantly decreased levels of collagen were observed in the AD group of Rag1−/− mice (1.6 ± 0.0 μg/mg vs. 4.5 ± 0.3 μg/mg, P < 0.001).
Conclusion
In the Af-induced AD-like murine model, type 2 ILCs were elevated, with increased levels of collagen. Additionally, removal of type 2 ILCs resulted in decreased collagen levels and improved AD-like pathological findings. These findings suggest that type 2 ILCs play a role in the mechanism of skin fibrosis in AD.
3.ChatGPT’s Potential in Dermatology Knowledge Retrieval:An Analysis Using Korean Dermatology Residency Examination Questions
Korean Journal of Dermatology 2024;62(3):143-151
Background:
The rapid evolution of artificial intelligence (AI), particularly large language models such as OpenAI’s ChatGPT, has significantly impacted various domains including healthcare. Dermatology can potentially benefit from the integration of ChatGPT.
Objective:
To analyze the performance of ChatGPT in dermatology, with particular focus on understanding the model’s capabilities and limitations when addressing dermatology questions.
Methods:
We employed 144 questions from Korean Dermatology Residency Evaluation Examinations. Questions were formatted consistently and fed to both GPT-4 and GPT-3.5 models. Performance was qualitatively assessed based on accuracy, completeness, and logical reasoning. Reasons for wrong answers were analyzed.
Results:
The overall correctness rate for GPT-4 was 70.8% and 59.0% for GPT-3.5. In terms of accuracy, 70.1% of the explanations were completely accurate. A total of 90.3% of responses provided by GPT-4 were complete in terms of content. Illogical reasoning was detected only in 4.9% of the answers. A total of 69.0% of wrong answers were attributed to information errors, followed by logical errors in 16.7%. There was no significant difference in the correctness rates among question types, but the correctness rate decreased significantly with question difficulty. ChatGPT showed near-perfect consistency, demonstrating a 97.9% agreement and a Cohen’s kappa of 0.958.
Conclusion
This study demonstrated the potential of ChatGPT in dermatology knowledge retrieval, outperforming dermatology residents in terms of correctness rate, completeness, and accuracy. There were more information errors than logical errors, and the inaccuracy caused by these errors was identified as the main limiting factor of ChatGPT.
4.Health-Seeking Behavior Returning to Normalcy Overcoming COVID-19 Threat in Breast Cancer
Eun-Gyeong LEE ; Yireh HAN ; Dong-Eun LEE ; Hyeong-Gon MOON ; Hyoung Won KOH ; Eun-Kyu KIM ; So-Youn JUNG
Cancer Research and Treatment 2023;55(4):1222-1230
Purpose:
The coronavirus disease 2019 (COVID-19) outbreak has significantly impacted the diagnosis and treatment of breast cancer. Our study investigated the change in diagnosis and treatment of breast cancer with the progress of COVID-19 pandemic.
Materials and Methods:
The study group comprised 6,514 recently diagnosed breast cancer patients between January 1, 2019, and February 28, 2021. The patients were divided into two groups: pre–COVID-19 period (3,182; January 2019 to December 2019) and COVID-19 pandemic period (3,332; January 2020 to February 2021). Clinicopathological information related to the first treatment after breast cancer diagnosis was retrospectively collected and analyzed in the two groups.
Results:
Among the 6,514 breast cancer patients, 3,182 were in the pre–COVID-19 period and 3,332 were in the COVID-19 pandemic period. According to our evaluation, the least breast cancer diagnosis (21.8%) was seen in the first quarter of 2020. The diagnosis increased gradually except for the fourth quarter in 2020. While early-stage breast cancer was diagnosed 1,601 (48.1%) during the COVID-19 pandemic (p=0.001), the number of surgical treatments increased 4.6% (p < 0.001), and the treatment time was slightly shorter 2 days (p=0.001). The breast cancer subtype distribution was not statistically different between the pre–COVID-19 and COVID-19 period groups.
Conclusion
In the early stages of the pandemic, the number of breast cancer cases temporarily decreased; however, they stabilized soon, and no significant differences could be identified in the diagnosis and treatment when compared to the period before the pandemic.
5.Stroke-Specific Predictors of Major Bleeding in Anticoagulated Patients With Stroke and Atrial Fibrillation: A Nationwide Multicenter Registry-Based Study
Darda CHUNG ; Tae-Jin SONG ; Bum Joon KIM ; Sung Hyuk HEO ; Jin-Man JUNG ; Kyungmi OH ; Chi Kyung KIM ; Sungwook YU ; Kwang Yeol PARK ; Jeong-Min KIM ; Jong-Ho PARK ; Man-Seok PARK ; Joon-Tae KIM ; Yang-Ha HWANG ; Yong-Jae KIM ; Jong-Won CHUNG ; Oh Young BANG ; Gyeong-Moon KIM ; Woo-Keun SEO ; Jay Chol CHOI
Journal of Clinical Neurology 2023;19(5):429-437
Background:
and Purpose The congestive heart failure, hypertension, age, diabetes, previous stroke/transient ischemic attack (CHA2DS2-VASc) and hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile international normalized ratio, elderly, drugs/alcohol (HAS-BLED) scores have been validated in estimating the risks of ischemic stroke and major bleeding, respectively, in patients with atrial fibrillation (AF). This study investigated stroke-specific predictors of major bleeding in patients with stroke and AF who were taking oral anticoagulants (OACs).
Methods:
Subjects were selected from patients enrolled in the Korean ATrial fibrillaTion EvaluatioN regisTry in Ischemic strOke patieNts (K-ATTENTION) nationwide multicenter registry between 2013 and 2015. Patients were excluded if they were not taking OACs, had no brain imaging data, or had intracranial bleeding directly related to the index stroke. Major bleeding was defined according to International Society of Thrombosis and Haemostasis criteria. Cox regression analyses were performed to assess the associations between clinical variables and major bleeding and Kaplan-Meier estimates were performed to analyze event-free survival.
Results:
Of a total of 3,213 patients, 1,414 subjects (mean age of 72.6 years, 52.5% males) were enrolled in this study. Major bleeding was reported in 34 patients during the median follow-up period of 1.73 years. Multivariable analysis demonstrated that initial National Institutes of Health Stroke Scale scores (hazard ratio [HR] 1.07, p=0.006), hypertension (HR 3.18, p=0.030), persistent AF type (HR 2.51, p=0.016), and initial hemoglobin level (HR 0.74, p=0.001) were independently associated with major bleeding risk. Except for hypertension, these associations remained significant after adjusting for the HAS-BLED score. Intracranial atherosclerosis presented a trend of association without statistical significance (HR 2.21, p=0.050).
Conclusions
This study found that major bleeding risk was independently associated with stroke-specific factors in anticoagulated patients with stroke and AF. This has the clinical implication that baseline characteristics of patients with stroke and AF should be considered in secondary prevention, which would bring the net clinical benefit of balancing recurrent stroke prevention with minimal bleeding complications.
6.Medial Arterial Calcification and the Risk of Amputation of Diabetic Foot Ulcer in Patients With Diabetic Kidney Disease
Joon Myeong SO ; Ji Ho PARK ; Jin Gyeong KIM ; Il Rae PARK ; Eun Yeong HA ; Seung Min CHUNG ; Jun Sung MOON ; Chul Hyun PARK ; Woo-Sung YUN ; Tae-Gon KIM ; Woong KIM ; Ji Sung YOON ; Kyu Chang WON ; Hyoung Woo LEE
Journal of Korean Medical Science 2023;38(21):e160-
We assessed the risk factors for major amputation of diabetic foot ulcers (DFUs) in patients with diabetic kidney disease (DKD) stages 3b–5. For DFU assessment, in addition to DFU location and presence of infection, ischemia, and neuropathy, vascular calcification was assessed using the medial arterial calcification (MAC) score. Of 210 patients, 26 (12.4%) underwent major amputations. Only the location and extension of DFU, represented by Texas grade differed between the minor and major amputation groups. However, after adjusting for covariates, ulcer location of mid- or hindfoot (vs. forefoot, odds ratio [OR] = 3.27), Texas grades 2 or 3 (vs. grade 0, OR = 5.78), and severe MAC (vs. no MAC, OR = 4.46) was an independent risk factor for major amputation (all P < 0.05). The current use of antiplatelets was a possible protective factor for major amputations (OR = 0.37, P = 0.055). In conclusion, DFU with severe MAC is associated with major amputation in patients with DKD.
7.Circulating Extracellular-Vesicle-Incorporated MicroRNAs as Potential Biomarkers for Ischemic Stroke in Patients With Cancer
Oh Young BANG ; Eun Hee KIM ; Mi Jeong OH ; Jaein YOO ; Gyun Sik OH ; Jong-Won CHUNG ; Woo-Keun SEO ; Gyeong-Moon KIM ; Myung-Ju AHN ; Seong Wook YANG ;
Journal of Stroke 2023;25(2):251-265
Background:
and Purpose This study aimed to evaluate whether extracellular-vesicle-incorporated microRNAs (miRNAs) are potential biomarkers for cancer-related stroke.
Methods:
This cohort study compared patients with active cancer who had embolic stroke of unknown sources (cancer-stroke group) with patients with only cancer, patients with only stroke, and healthy individuals (control groups). The expression profiles of miRNAs encapsulated in plasma exosomes and microvesicles were evaluated using microarray and validated using quantitative real-time polymerase chain reaction. The XENO-QTM miRNA assay technology was used to determine the absolute copy numbers of individual miRNAs in an external validation cohort.
Results:
This study recruited 220 patients, of which 45 had cancer-stroke, 76 were healthy controls, 39 were cancer controls, and 60 were stroke controls. Three miRNAs (miR-205-5p, miR-645, and miR-646) were specifically incorporated into microvesicles in patients with cancer-related stroke, cancer controls, and stroke controls. The area under the receiver operating characteristic curves of these three miRNAs were 0.7692–0.8510 for the differentiation of patients with cancer-stroke from cancer-controls and 0.8077–0.8846 for the differentiation of patients with cancer-stroke from stroke controls. The levels of several miRNAs were elevated in the plasma exosomes of patients with cancer, but were lower than those in plasma microvesicles. An in vivo study showed that systemic injection of miR-205-5p promoted the development of arterial thrombosis and elevation of D-dimer levels.
Conclusion
Stroke due to cancer-related coagulopathy was associated with deregulated expression of miRNAs, particularly microvesicle-incorporated miR-205-5p, miR-645, and miR-646. Further prospective studies of extracellular-vesicle-incorporated miRNAs are required to confirm the diagnostic role of miRNAs in patients with stroke and to screen the roles of miRNAs in patients with cancer.
8.A Drug-Induced Sarcoidosis-Like Reaction in Lung Cancer Patient Treated with Nivolumab and Ipilimumab: A Case Report and Literature Review
Soo Hyung KIM ; Seo Gyeong LEE ; Ji Yoon KIM ; Hyun Jeong JU ; Gyong Moon KIM ; Ji Hae LEE
Korean Journal of Dermatology 2022;60(3):182-185
Immune checkpoint inhibitor (ICI), including programmed cell death protein 1 and cytotoxic T-lymphocyte-associated protein 4 inhibitors, has emerged as a pillar in the management of advanced malignancies. A drug-induced sarcoidosis-like reaction (DISR) is a rare cutaneous adverse event of ICI. A 47-year-old male presented with one-month history of a solitary erythematous nodule on his forehead. He had been diagnosed with metastatic adenocarcinoma of the lung and was treated with nivolumab and ipilimumab for three months. Histological findings revealed multinucleated giant cells forming non-caseating granulomas with moderate peripheral lymphocyte infiltration in the dermis. Also, new hilar lymphadenopathy of the lung was identified in a systemic evaluation. Given the temporal relationship with ICI treatment, the final diagnosis was ICI-induced sarcoidosis-like reaction. To our knowledge, this is the first report of a case of DISR that developed following ICI treatment in the dermatologic literature in Korea.
9.Diffusion-Weighted Imaging-Alone Endovascular Thrombectomy Triage in Acute Stroke: Simulating Diffusion-Perfusion Mismatch Using Machine Learning
Yoon-Chul KIM ; Woo-Keun SEO ; In-Young BAEK ; Ji-Eun LEE ; Ha-Na SONG ; Jong-Won CHUNG ; Chi Kyung KIM ; Kyungmi OH ; Sang-il SUH ; Oh Young BANG ; Gyeong-Moon KIM ; Jeffrey L. SAVER ; David S. LIEBESKIND
Journal of Stroke 2022;24(1):148-151
10.Vessel Wall Changes on Serial High-Resolution MRI and the Use of Cilostazol in Patients With Adult-Onset Moyamoya Disease
Jae Youn KIM ; Hyung Jun KIM ; Eun-Hyeok CHOI ; Kwang Hyun PAN ; Jong-Won CHUNG ; Woo-Keun SEO ; Gyeong-Moon KIM ; Tae Keun JEE ; Je Young YEON ; Jong-Soo KIM ; Seung-Chyul HONG ; Min-Jung SEONG ; Jihoon CHA ; Keon Ha KIM ; Pyoung JEON ; Oh Young BANG
Journal of Clinical Neurology 2022;18(6):610-618
Background:
and Purpose The natural course of adult-onset moyamoya disease (MMD) is unknown, and there is no medical treatment that halts its progression. We hypothesized that progressive shrinkage of large intracranial arteries occurs in adult-onset MMD, and that cilostazol inhibits this process.
Methods:
Serial high-resolution magnetic resonance imaging (HR-MRI) was performed on 66 patients with MMD: 30 patients received cilostazol, 21 received other antiplatelets, and 15 received no antiplatelets or had poor compliance to them. Serial HR-MRI was performed (interval between MRI scans: 29.67±18.02 months, mean±SD), and changes in outer diameter, luminal stenosis, and vascular enhancement were measured. Factors affecting HR-MRI changes were evaluated, including vascular risk factors and the ring finger protein 213 gene variant.
Results:
The progression of stenosis to occlusion, recurrent ischemic stroke, and the development of new stenotic segments were observed in seven, seven, and three patients, respectively. Serial HR-MRI indicated that the degree of stenosis increased with negative remodeling (outer diameter shrinkage). Patients who received cilostazol presented significantly larger outer diameters and lower degrees of stenosis compared with other groups (p=0.005 and p=0.031, respectively). After adjusting for clinical and genetic factors, only cilostazol use was independently associated with negative remodeling (odds ratio=0.29, 95% confidence interval=0.10–0.84, p=0.023). While vascular enhancement was observed in most patients (61 patients), the progression of enhancement or the occurrence of new vascular enhancement was rarely observed on follow-up HR-MRI (6 and 1 patients, respectively).
Conclusions
Adult-onset MMD induces progressive shrinkage of large intracranial arteries, which cilostazol treatment may prevent. Further randomized clinical trials are warranted.

Result Analysis
Print
Save
E-mail